Tirzepatide, the recently approved medication, is creating considerable interest within the healthcare community. It operates differently from common diabetes therapies , targeting two receptors involved in sugar regulation and hunger . Initial trials have demonstrated impressive efficacy in reducing blood sugar in individuals with diabetes of the